What question did this study set out to answer?

August 2, 2026PharmacoEconomics - OpenOpen Access

AMPLIFY: Estimating Clinical and Humanistic Benefits of Pembrolizumab in Portugal

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial estimates significant clinical gains from pembrolizumab use in Portugal, suggesting improved access could enhance health outcomes.

This research aims to estimate the clinical and humanistic benefits of pembrolizumab in Portugal from 2017 to 2024, with projections until 2030.
Developed a tool in Microsoft Excel to aggregate outputs from validated cost-effectiveness models for pembrolizumab in Portugal.
Estimated clinical outcomes based on the real-world number of treated patients, including incremental life years and quality-adjusted life years.
Forecasted potential future benefits and assessed alternative scenarios for reimbursement and patient access.
From 2017 to 2024, pembrolizumab was linked to 14,042 incremental QALYs and 17,914 incremental LYs among 13,530 treated patients.
Accelerated reimbursement could have led to an additional 14,705 QALYs and 1250 avoided deaths, totaling 28,746 QALYs and 3271 avoided deaths.
Future projections estimate approximately 31,306 QALYs and 38,274 LYs for patients treated between 2025 and 2030.

Cardoso et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

August 2, 2026PharmacoEconomics - OpenOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial estimates significant clinical gains from pembrolizumab use in Portugal, suggesting improved access could enhance health outcomes.

This research aims to estimate the clinical and humanistic benefits of pembrolizumab in Portugal from 2017 to 2024, with projections until 2030.
Developed a tool in Microsoft Excel to aggregate outputs from validated cost-effectiveness models for pembrolizumab in Portugal.
Estimated clinical outcomes based on the real-world number of treated patients, including incremental life years and quality-adjusted life years.
Forecasted potential future benefits and assessed alternative scenarios for reimbursement and patient access.
From 2017 to 2024, pembrolizumab was linked to 14,042 incremental QALYs and 17,914 incremental LYs among 13,530 treated patients.
Accelerated reimbursement could have led to an additional 14,705 QALYs and 1250 avoided deaths, totaling 28,746 QALYs and 3271 avoided deaths.
Future projections estimate approximately 31,306 QALYs and 38,274 LYs for patients treated between 2025 and 2030.

Cardoso et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark